Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A company is trying to unlock a key to aging, in a long-overlooked body part - 2The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
- 3Images of Bangladeshi motorcyclists sleeping at petrol pumps are AI-generated
- 4Which Diet Prompts the Incomparable Wellbeing Results?
- 5Home Security Frameworks with Shrewd Elements
- Three killed as unfinished building collapses on church service in Ghana
- SpaceX launches Italian Earth-observing satellite to orbit on the 1st mission of 2026 (video)
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- Strength training is crucial after menopause. How to make the most of your workouts
- Viable Monetary Tips to Advance Your Monetary Circumstance
- First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- 15 Preposterous Cosplay Ensembles That Will Blow You Away
- Germany expresses 'great concern' over Israel's new death penalty law
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
